Mass screening of hepatitis B and C in Burkina Faso: seroprevalence update and impact of hepatitis B vaccine
Introduction: Updated data on the seroprevalences of hepatitis B and C viruses (HBV, HCV) are required to enable the adaptation of control strategies. In this study, we aimed to: (i) estimate the seroprevalences of HBsAg carriers and HCV exposure in the general population, and (ii) determine the im...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2024-09-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/19673 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850193155670933504 |
|---|---|
| author | Armel Moumouni Sanou Delphine Napon-Zongo Abou Coulibaly Ina Marie Angèle Traore Ad Bafa Ibrahim Ouattara Abdoul Kader Ilboudo Abdou Azaque Zoure Sylvie Zida Mathuola Nina Geneviève Ouattara Abdoulaye Dera Djara Konate Eric Kyelem Achille Sindimbasba Nikiema David Lankoande Dieudonné Ilboudo Dramane Kania |
| author_facet | Armel Moumouni Sanou Delphine Napon-Zongo Abou Coulibaly Ina Marie Angèle Traore Ad Bafa Ibrahim Ouattara Abdoul Kader Ilboudo Abdou Azaque Zoure Sylvie Zida Mathuola Nina Geneviève Ouattara Abdoulaye Dera Djara Konate Eric Kyelem Achille Sindimbasba Nikiema David Lankoande Dieudonné Ilboudo Dramane Kania |
| author_sort | Armel Moumouni Sanou |
| collection | DOAJ |
| description |
Introduction: Updated data on the seroprevalences of hepatitis B and C viruses (HBV, HCV) are required to enable the adaptation of control strategies. In this study, we aimed to: (i) estimate the seroprevalences of HBsAg carriers and HCV exposure in the general population, and (ii) determine the impact of vaccination on HBV circulation since its introduction in 2006 in the Expanded Program on Immunization (EPI).
Methodology: From October 2020 to October 2022, a mass screening campaign was conducted in 10 cities across Burkina Faso. Individuals of all ages and genders who consented to participate were screened for viral markers (HBsAg, anti-HCV) using rapid diagnostic tests. The proportions of HBsAg carriers and HCV exposure were calculated using Stata, and logistic regression was used to assess the impact of HBV vaccination on HBsAg carriage.
Results: A total of 15,650 participants were enrolled in the study. Of these, 51.4% were women and the age range was from 1 to 97 years. All participants were screened for HBsAg and 7,507 were also screened for anti-HCV. Overall, the seroprevalence of HBsAg was 8.8% and 2.6% for anti-HCV. The results indicated that age, gender, and place of residence were associated with HBV infection.
Conclusions: The prevalence of HBV and HCV infections remains high in Burkina Faso. Prevention strategies, including initial mass screening with rapid diagnostic tests and vaccination, need to be intensified.
|
| format | Article |
| id | doaj-art-db59b33bef8b4b7eacd4d9cf7b44c0e3 |
| institution | OA Journals |
| issn | 1972-2680 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | The Journal of Infection in Developing Countries |
| record_format | Article |
| series | Journal of Infection in Developing Countries |
| spelling | doaj-art-db59b33bef8b4b7eacd4d9cf7b44c0e32025-08-20T02:14:20ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802024-09-01180910.3855/jidc.19673Mass screening of hepatitis B and C in Burkina Faso: seroprevalence update and impact of hepatitis B vaccineArmel Moumouni Sanou0Delphine Napon-Zongo1Abou Coulibaly2Ina Marie Angèle Traore3Ad Bafa Ibrahim Ouattara4Abdoul Kader Ilboudo5Abdou Azaque Zoure6Sylvie Zida7Mathuola Nina Geneviève Ouattara8Abdoulaye Dera9Djara Konate10Eric Kyelem11Achille Sindimbasba Nikiema12David Lankoande13Dieudonné Ilboudo14Dramane Kania15Laboratoire de Recherche sur les Maladies Infectieuses et Parasitaires (LR-MIP), Institut de Recherche en Sciences de la Santé (IRSS), 01 BP 545 Bobo-Dioulasso, Burkina FasoInstitut Supérieur des Sciences de la Santé (INSSA), Université Nazi Boni, Bobo-Dioulasso, Burkina FasoLaboratoire de Recherche en Santé Publique et Nutrition (LR-SPN), Institut de Recherche en Sciences de la Santé (IRSS), Burkina FasoLaboratoire de Recherche sur les Maladies Infectieuses et Parasitaires (LR-MIP), Institut de Recherche en Sciences de la Santé (IRSS), 01 BP 545 Bobo-Dioulasso, Burkina FasoDépartement Clinique, Centre Assaut-Hépatites, Bobo-Dioulasso, Burkina FasoLaboratoire de Recherche sur les Maladies Infectieuses et Parasitaires (LR-MIP), Institut de Recherche en Sciences de la Santé (IRSS), 01 BP 545 Bobo-Dioulasso, Burkina FasoLaboratoire de Recherche sur les Maladies Infectieuses et Parasitaires (LR-MIP), Institut de Recherche en Sciences de la Santé (IRSS), 01 BP 545 Bobo-Dioulasso, Burkina FasoLaboratoire de Recherche sur les Maladies Infectieuses et Parasitaires (LR-MIP), Institut de Recherche en Sciences de la Santé (IRSS), 01 BP 545 Bobo-Dioulasso, Burkina FasoLaboratoire de Recherche sur les Maladies Infectieuses et Parasitaires (LR-MIP), Institut de Recherche en Sciences de la Santé (IRSS), 01 BP 545 Bobo-Dioulasso, Burkina FasoLaboratoire de Recherche sur les Maladies Infectieuses et Parasitaires (LR-MIP), Institut de Recherche en Sciences de la Santé (IRSS), 01 BP 545 Bobo-Dioulasso, Burkina FasoDépartement des laboratoires, Centre Assaut-Hépatites, Bobo-Dioulasso, Burkina FasoLaboratoire de Recherche sur les Maladies Infectieuses et Parasitaires (LR-MIP), Institut de Recherche en Sciences de la Santé (IRSS), 01 BP 545 Bobo-Dioulasso, Burkina FasoLaboratoire de Recherche sur les Maladies Infectieuses et Parasitaires (LR-MIP), Institut de Recherche en Sciences de la Santé (IRSS), 01 BP 545 Bobo-Dioulasso, Burkina FasoDépartement Clinique, Centre Assaut-Hépatites, Bobo-Dioulasso, Burkina FasoDépartement Clinique, Centre Assaut-Hépatites, Bobo-Dioulasso, Burkina FasoCentre MURAZ, Institut National de Santé Publique, Burkina Faso Introduction: Updated data on the seroprevalences of hepatitis B and C viruses (HBV, HCV) are required to enable the adaptation of control strategies. In this study, we aimed to: (i) estimate the seroprevalences of HBsAg carriers and HCV exposure in the general population, and (ii) determine the impact of vaccination on HBV circulation since its introduction in 2006 in the Expanded Program on Immunization (EPI). Methodology: From October 2020 to October 2022, a mass screening campaign was conducted in 10 cities across Burkina Faso. Individuals of all ages and genders who consented to participate were screened for viral markers (HBsAg, anti-HCV) using rapid diagnostic tests. The proportions of HBsAg carriers and HCV exposure were calculated using Stata, and logistic regression was used to assess the impact of HBV vaccination on HBsAg carriage. Results: A total of 15,650 participants were enrolled in the study. Of these, 51.4% were women and the age range was from 1 to 97 years. All participants were screened for HBsAg and 7,507 were also screened for anti-HCV. Overall, the seroprevalence of HBsAg was 8.8% and 2.6% for anti-HCV. The results indicated that age, gender, and place of residence were associated with HBV infection. Conclusions: The prevalence of HBV and HCV infections remains high in Burkina Faso. Prevention strategies, including initial mass screening with rapid diagnostic tests and vaccination, need to be intensified. https://jidc.org/index.php/journal/article/view/19673Hepatitis Bhepatitis Cseroprevalencemass screeningepidemiologyBurkina Faso |
| spellingShingle | Armel Moumouni Sanou Delphine Napon-Zongo Abou Coulibaly Ina Marie Angèle Traore Ad Bafa Ibrahim Ouattara Abdoul Kader Ilboudo Abdou Azaque Zoure Sylvie Zida Mathuola Nina Geneviève Ouattara Abdoulaye Dera Djara Konate Eric Kyelem Achille Sindimbasba Nikiema David Lankoande Dieudonné Ilboudo Dramane Kania Mass screening of hepatitis B and C in Burkina Faso: seroprevalence update and impact of hepatitis B vaccine Journal of Infection in Developing Countries Hepatitis B hepatitis C seroprevalence mass screening epidemiology Burkina Faso |
| title | Mass screening of hepatitis B and C in Burkina Faso: seroprevalence update and impact of hepatitis B vaccine |
| title_full | Mass screening of hepatitis B and C in Burkina Faso: seroprevalence update and impact of hepatitis B vaccine |
| title_fullStr | Mass screening of hepatitis B and C in Burkina Faso: seroprevalence update and impact of hepatitis B vaccine |
| title_full_unstemmed | Mass screening of hepatitis B and C in Burkina Faso: seroprevalence update and impact of hepatitis B vaccine |
| title_short | Mass screening of hepatitis B and C in Burkina Faso: seroprevalence update and impact of hepatitis B vaccine |
| title_sort | mass screening of hepatitis b and c in burkina faso seroprevalence update and impact of hepatitis b vaccine |
| topic | Hepatitis B hepatitis C seroprevalence mass screening epidemiology Burkina Faso |
| url | https://jidc.org/index.php/journal/article/view/19673 |
| work_keys_str_mv | AT armelmoumounisanou massscreeningofhepatitisbandcinburkinafasoseroprevalenceupdateandimpactofhepatitisbvaccine AT delphinenaponzongo massscreeningofhepatitisbandcinburkinafasoseroprevalenceupdateandimpactofhepatitisbvaccine AT aboucoulibaly massscreeningofhepatitisbandcinburkinafasoseroprevalenceupdateandimpactofhepatitisbvaccine AT inamarieangeletraore massscreeningofhepatitisbandcinburkinafasoseroprevalenceupdateandimpactofhepatitisbvaccine AT adbafaibrahimouattara massscreeningofhepatitisbandcinburkinafasoseroprevalenceupdateandimpactofhepatitisbvaccine AT abdoulkaderilboudo massscreeningofhepatitisbandcinburkinafasoseroprevalenceupdateandimpactofhepatitisbvaccine AT abdouazaquezoure massscreeningofhepatitisbandcinburkinafasoseroprevalenceupdateandimpactofhepatitisbvaccine AT sylviezida massscreeningofhepatitisbandcinburkinafasoseroprevalenceupdateandimpactofhepatitisbvaccine AT mathuolaninagenevieveouattara massscreeningofhepatitisbandcinburkinafasoseroprevalenceupdateandimpactofhepatitisbvaccine AT abdoulayedera massscreeningofhepatitisbandcinburkinafasoseroprevalenceupdateandimpactofhepatitisbvaccine AT djarakonate massscreeningofhepatitisbandcinburkinafasoseroprevalenceupdateandimpactofhepatitisbvaccine AT erickyelem massscreeningofhepatitisbandcinburkinafasoseroprevalenceupdateandimpactofhepatitisbvaccine AT achillesindimbasbanikiema massscreeningofhepatitisbandcinburkinafasoseroprevalenceupdateandimpactofhepatitisbvaccine AT davidlankoande massscreeningofhepatitisbandcinburkinafasoseroprevalenceupdateandimpactofhepatitisbvaccine AT dieudonneilboudo massscreeningofhepatitisbandcinburkinafasoseroprevalenceupdateandimpactofhepatitisbvaccine AT dramanekania massscreeningofhepatitisbandcinburkinafasoseroprevalenceupdateandimpactofhepatitisbvaccine |